메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
연세대학교 의과대학 Yonsei Medical Journal Yonsei Medical Journal 제59권 제4호
발행연도
2018.1
수록면
470 - 479 (10page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Purpose: Cell-free DNA (cfDNA) is gaining attention as a novel biomarker for oncologic outcomes. We investigated the clinicalsignificance of cfDNA in hepatocellular carcinoma (HCC) patients treated with radiotherapy (RT). Materials and Methods: Fifty-five patients with HCC who received RT were recruited from two prospective study cohorts: onecohort of 34 patients who underwent conventionally fractionated RT and a second of 21 patients treated with stereotactic bodyradiation therapy. cfDNA was extracted and quantified. Results: In total, 30% of the patients had multiple tumors, 77% had tumors >2 cm, and 32% had portal vein tumor thrombus. Optimalcut-off values for cfDNA levels (33.65 ng/mL and 37.25 ng/mL, before and after RT) were used to divide patients into low-DNA(LDNA) and high-DNA (HDNA) groups. The pre-RT HDNA group tended to have more advanced disease and larger tumors(p=0.049 and p=0.017, respectively). Tumor response, intrahepatic failure-free rates, and local control (LC) rates were significantlybetter in the post-RT LDNA group (p=0.017, p=0.035, and p=0.006, respectively). Conclusion: Quantitative analysis of cfDNA was feasible in our cohorts. Post-RT cfDNA levels were negatively correlated with treatmentoutcomes, indicating the potential for the use of post-RT cfDNA levels as an early predictor of treatment responses and LCafter RT for HCC patients.

목차

등록된 정보가 없습니다.

참고문헌 (37)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0